会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 51. 发明授权
    • Capsule-type endoscope system, and program and method used for the system
    • 胶囊型内窥镜系统,以及用于该系统的程序和方法
    • US08303486B2
    • 2012-11-06
    • US12134775
    • 2008-06-06
    • Manabu Fujita
    • Manabu Fujita
    • A61B1/00
    • A61B1/00043A61B1/00016A61B1/00022A61B1/00059A61B1/041A61B5/073A61B2560/045G06F19/00
    • A capsule-type endoscope system includes plural receivers, plural mounting spots for mounting the receivers and an information processing apparatus connected to the receivers via the mounting spots. Each receiver wirelessly receives image data from a capsule-type endoscope that images inside of an examinee's body; stores examinee identification information and the received image data; and displays the examinee identification information or examinee information associated therewith. The information processing apparatus receives the examinee identification information from each receiver via the mounting spot and manages its correlation with receiver identification information or mounting spot identification information. The image data is transmitted via the mounting spot to the information processing apparatus to be stored therein. The information processing apparatus displays the correlation by displaying at least a part of the examinee identification information or examinee information, and displays the progress of the transmission of image data corresponding to each receiver.
    • 胶囊型内窥镜系统包括多个接收器,用于安装接收器的多个安装点和经由安装点连接到接收器的信息处理设备。 每个接收器从被检体内部的胶囊型内窥镜无线地接收图像数据; 存储被检体识别信息和接收到的图像数据; 并显示与其相关联的受检者识别信息或受检者信息。 信息处理装置经由安装点从各接收机接收受检者识别信息,并管理其与接收者识别信息或安装点识别信息的相关性。 图像数据经由安装点传送到信息处理装置以被存储在其中。 信息处理装置通过显示至少一部分受检者识别信息或受检者信息来显示相关性,并且显示与每个接收器相对应的图像数据的传输进度。
    • 54. 发明授权
    • Receiving apparatus
    • 接收装置
    • US08002693B2
    • 2011-08-23
    • US11571421
    • 2006-09-01
    • Toshiaki ShigemoriManabu FujitaAyako NagaseAkira MatsuiKazutaka Nakatsuchi
    • Toshiaki ShigemoriManabu FujitaAyako NagaseAkira MatsuiKazutaka Nakatsuchi
    • A61B1/00
    • A61B1/00036A61B1/00016A61B1/041A61B5/07A61B2560/0209
    • A condition for determining that an examination by a capsule endoscope 3 (body insertable device) completes is set in advance. When a predetermined time period has passed since the examination starts, and when received electric-field strength of receiving antennas A1 to An detected during a predetermined time period is not higher than a predetermined value, the examination is determined to have been completed. An examination completion determining unit C1 determines whether the condition is satisfied or not. According to the result of determination, a notification controller C2 makes a notifying unit 15 notify that the examination completes, and a power supply controller C3 stop power supply to a radio unit 2a. Thus, unnecessary power consumption is prevented and the completion of the examination by the body insertable device is recognized.
    • 预先设定用于确定胶囊型内窥镜3(身体可插入装置)的检查完成的判定条件。 当从检查开始经过预定时间段时,并且当在预定时间段内检测到的接收天线A1至An的接收电场强度不高于预定值时,确定检查已经完成。 检查完成确定单元C1确定条件是否满足。 根据确定结果,通知控制器C2使通知单元15通知检查完成,并且电源控制器C3停止向无线电单元2a供电。 因此,防止了不必要的电力消耗,并且识别出被主体插入装置的检查完成。
    • 60. 发明申请
    • Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
    • 包含与活性成分相同的托烷化合物和药物组合物
    • US20080027094A1
    • 2008-01-31
    • US11661310
    • 2005-08-29
    • Hisao NakaiToshihiko NishiyamaNobuyuki NakamuraManabu Fujita
    • Hisao NakaiToshihiko NishiyamaNobuyuki NakamuraManabu Fujita
    • A61K31/46A61P11/06C07D451/02
    • C07D451/06A61K31/00
    • The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X− is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.
    • 通过吸入给药的常规抗胆碱能药物被认为具有加重与血液介导的前列腺增生相关的排尿困难的可能性,并且已经要求用于通过吸入给药的常规抗胆碱能药物必须显示减少的副作用或不良反应 。 本发明涉及由通式(I)表示的化合物:(其中A表示; R 1,R 2,R 3, 和R 1各自为氢原子或取代基; R 5为取代基; X为 - 阴离子;符号为:img id =“custom-character-00001”he =“2.46mm”wi =“3.89mm”file =“US20080027094A1-20080131-P00001.TIF”img-content =“character”img-format =“tif”/> 外部形式或内在形式,或其混合物),其盐或溶剂化产物。 它们可用作对由毒蕈碱受体介导的疾病的副作用或不良反应降低的预防和/或治疗剂。